Cardiac resynchronization therapy versus left bundle branch area pacing for atrioventricular block and heart failure (BLOCK NAGOYA STUDY)

Cardiac resynchronization therapy versus left bundle branch area pacing in patients with atrioventricular block and mild to moderate heart failure: A prospective multicenter study (BLOCK NAGOYA PACING STUDY)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs042240129

Enrollment

Registered

2024-11-22

Start date

2024-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrioventricular block, chronic heart failure Atrioventricular block, chronic heart failure

Interventions

Patients are randomly assigned to therapeutic groups of LBBBAP pacing and CRT pacing. All patients are examined by echocardiography, blood examination test, and electrocardiogram six months after the

An improvement of LVEF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients indicated for newly permanent pacemaker implantation due to advanced atrioventricular block (second and third degree). Patients with complicated heart failure and moderately decreased left ventricular ejection function (35-50%) before implantation. High frequency of ventricular pacing with >40% after implantation.

Exclusion criteria

Exclusion criteria: Patients indicated for defibrillator lead implantation Patients who are not required for permanent pacemaker implantation owing to temporal atrioventricular block Anatomical difficulty of transvenous lead implantation Upgrading cases from prior pacemaker devices or re-implantation cases Inability to obtain informed consent from a patient

Design outcomes

Primary

Measure	Time frame
An improvement of LVEF from before to after 6 months	—

Secondary

Measure	Time frame
An improvement of BNP levels from before to after 6 months An improvement of LVEDV, LVESV, LVDd, and LVDs from before to after 6 months Pacing QRS duration at 6 months after implantation Heart failure hospitalization and ventricular arrhythmia events after 2 years Adverse events after 2 years (lead dislodgement, lead re-implantation, lead fracture, device infection, lead perforation, bleeding, and all-cause death)	—

Measure

Time frame

An improvement of BNP levels from before to after 6 months An improvement of LVEDV, LVESV, LVDd, and LVDs from before to after 6 months Pacing QRS duration at 6 months after implantation Heart failure hospitalization and ventricular arrhythmia events after 2 years Adverse events after 2 years (lead dislodgement, lead re-implantation, lead fracture, device infection, lead perforation, bleeding, and all-cause death)

—

Contacts

Public ContactSatoshi Yanagisawa

Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine

yanagisawa-sato@med.nagoya-u.ac.jp81-52-744-2148

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026